Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease

Rheumatology (Oxford). 2010 Jun;49(6):1118-27. doi: 10.1093/rheumatology/keq005. Epub 2010 Mar 15.

Abstract

Objectives: Patients with inflammatory rheumatic diseases (IRDs) have a higher morbidity and mortality from accelerated atherosclerosis than the general population. We hypothesized that patients with the combination of IRD and coronary artery disease (CAD) would have a certain inflammatory phenotype compared with CAD patients without this comorbidity.

Methods: Four groups of patients were included: patients with IRD, referred to coronary artery bypass grafting (CABG) (CAD-IRD, n = 67), patients without IRD, referred to CABG (CAD, n = 52), patients with IRD without CAD (IRD, n = 32) and healthy controls (n = 30). Plasma levels of several inflammatory markers were analysed by enzyme immunoassays.

Results: (i) Plasma levels of markers of endothelial cell activation [i.e. vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand factor] and osteoprotegerin (OPG) were significantly increased and plasma levels of CCL21 significantly decreased in CAD-IRD patients as compared with CAD patients without IRD. (ii) Within the CAD-IRD group, acute coronary syndrome was a significant predictor of OPG, suggesting an enhanced inflammatory response during plaque destabilization in CAD-IRD patients. (iii) Plasma levels of VCAM-1, OPG and CCL21, but not lipid parameters, IRD characteristics and several other inflammatory markers (e.g. CRP), were significant predictors of CAD-IRD as opposed to CAD in two logistic regression models.

Conclusion: Our findings further support a role for inflammation in the accelerated form of atherosclerosis in IRD patients, and suggest that certain inflammatory pathways, such as the enhanced endothelial cell activation and the RANK ligand/RANK/OPG system, may be of particular importance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / metabolism*
  • Case-Control Studies
  • Chemokines / metabolism*
  • Coronary Artery Disease / complications*
  • Coronary Artery Disease / metabolism
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Biological
  • Osteoprotegerin / metabolism*
  • Regression Analysis
  • Rheumatic Diseases / complications*
  • Rheumatic Diseases / metabolism
  • Risk Factors

Substances

  • Biomarkers
  • Chemokines
  • Osteoprotegerin